Table 1.
Characteristic | PBSC donors n (%) |
BM donors n (%) |
P value |
---|---|---|---|
No. of donors | 14 530 | 7123 | |
No. of filgrastim exposures, n (%) | |||
1 | 13 579 (93) | N/A | |
2 | 416 (3) | N/A | |
3 | 6 (<1) | N/A | |
No. of BM donations, n (%) | |||
1 | N/A | 6496 (91) | |
2 | N/A | 169 (2) | |
3 | N/A | 12 (<1) | |
No. of both BM donations and filgrastim exposures∗, n (%) | .846 | ||
1 BM donation,1 filgrastim exposure | 498 (3) | 416 (6) | |
1 BM donation, 2 filgrastim exposures | 13 (<1) | 12 (<1) | |
2 BM donations, 1 filgrastim exposure | 18 (<1) | 18 (<1) | |
Sex, n (%) | .019 | ||
Female | 5975 (41) | 3048 (43) | |
Male | 8 555 (59) | 4075 (57) | |
Race, n (%) | <.001 | ||
White | 10 980 (76) | 5070 (71) | |
Hispanic | 1 252 (9) | 798 (11) | |
Black | 498 (3) | 396 (6) | |
Asian/Pacific Islander | 800 (6) | 407 (6) | |
Native American | 103 (1) | 68 (1) | |
Multiple races/other | 848 (6) | 360 (5) | |
Unknown/decline | 49 (<1) | 24 (<1) | |
Age at first BM collection or first filgrastim injection, y, n (%) | <.001 | ||
Median (min-max) | 33 (18-62) | 35 (19-61) | <.001 |
18-29 | 5 896 (41) | 2542 (36) | |
30-39 | 3 871 (27) | 2186 (31) | |
40-49 | 3 231 (22) | 1804 (25) | |
50+ | 1 532 (11) | 591 (8) | |
Year of first BM collection or first filgrastim injection, n (%) | <.001 | ||
1989 | 0 | 1 (<1) | |
1990 | 0 | 4 (<1) | |
1991 | 0 | 3 (<1) | |
1992 | 0 | 7 (<1) | |
1993 | 0 | 19 (<1) | |
1994 | 0 | 9 (<1) | |
1995 | 0 | 10 (<1) | |
1996 | 0 | 25 (<1) | |
1997 | 0 | 30 <1) | |
1998 | 0 | 36 (1) | |
1999 | 15 (<1) | 281 (4) | |
2000 | 137 (1) | 492 (7) | |
2001 | 195 (1) | 435 (6) | |
2002 | 317 (2) | 457 (6) | |
2003 | 466 (3) | 375 (5) | |
2004 | 453 (3) | 307 (4) | |
2005 | 537 (4) | 243 (3) | |
2006 | 587 (4) | 272 (4) | |
2007 | 652 (4) | 276 (4) | |
2008 | 777 (5) | 280 (4) | |
2009 | 850 (6) | 297 (4) | |
2010 | 1 001 (7) | 329 (5) | |
2011 | 1 450 (10) | 510 (7) | |
2012 | 1 772 (12) | 656 (9) | |
2013 | 2 010 (14) | 656 (9) | |
2014 | 1 817 (13) | 625 (9) | |
2015 | 1 479 (10) | 484 (7) | |
2016 | 15 (<1) | 4 (<1) | |
Median (min-max) follow-up, y | 7.0 (0.6-20.2) | 9.0 (0.0-29.2) | <.001 |
N/A, not applicable; min, minimum; max, maximum; y, years.
Donors in the BM group who later had exposure to filgrastim were censored at the time of filgrastim exposure.